Test Catalog

Test ID: PCPDF    
Plasma Cell Proliferative Disorder (PCPD), FISH, Bone Marrow

Useful For Suggests clinical disorders or settings where the test may be helpful

Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders


Identifying prognostic markers based on the anomalies found

Reflex Tests Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test IDReporting NameAvailable SeparatelyAlways Performed
_PBCTProbe, +2No, (Bill Only)No
_PADDProbe, +1No, (Bill Only)No
_PB02Probe, +2No, (Bill Only)No
_PB03Probe, +3No, (Bill Only)No
_IL25Interphases, <25No, (Bill Only)No
_I099Interphases, 25-99No, (Bill Only)No
_I300Interphases, >=100 No, (Bill Only)No

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.


Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.


This test is designed for diagnostic specimens. Please indicate if the entire panel is to be performed. If the patient is being tracked for known abnormalities, indicate which probes should be used. Panel includes testing for the following abnormalities using the probes listed:


-13/13q-, RB1/LAMP1

t(11;14), CCND1/IGH

14q32 rearrangement, IGH

17p-, TP53/D17Z1

+3/+7, D3Z1/D7Z1

+9/+15, D9Z1/D15Z4

1q gain, TP73/1q22

8q24.1 rearrangement, MYC


When an IGH rearrangement is identified and the partner is not CCND1, reflex testing is performed to identify the translocation partner. Probes include identification of t(4;14)(p16.3;q32) FGFR3/IGH, t(6;14)(p21;q32) CCND3/IGH, t(14;16)(q32;q23) IGH/MAF, and t(14;20)(q32;q12) IGH/MAFB.


Initial screening will be performed to determine if sufficient plasma cells are present within the provided specimen.


For diagnostic samples (unless otherwise specified), all probes in the panel will be evaluated if sufficient plasma cells are identified.


For follow-up samples (unless otherwise specified), only TP73/1q22, TP53/Cen17 and MYC probes along with probes that were abnormal in a previous study will be tested. If a previous sample was uninformative due to an insufficient number of plasma cells, the complete panel will be evaluated (if sufficient plasma cells are identified).


This assay detects abnormalities observed in the bone marrow of patients with a plasma cell disorder. If a paraffin-embedded tissue sample is received, this test will be cancelled and PLASF / Plasma Cell Proliferative Disorder, FISH, Tissue will be added and performed as the appropriate test.  If a fixed cell pellet is received, this test will be cancelled and MFCF / Myeloma, FISH, Fixed Cells will be added and performed.


Method Name A short description of the method used to perform the test

Cytoplasmic Immunoglobulin (cIg) Staining Followed by Fluorescence In Situ Hybridization (FISH)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

Plasma Cell Prolif, cIg, FISH

Aliases Lists additional common names for a test, as an aid in searching

13q- / -13 (13q deletion) or RB1
17p- (17p deletion) or TP53
-13 (monosomy 13)
IGH (14q32) rearrangement
Monoclonal Gammopathy of Unknown Significance (MGUS)
Multiple Myeloma
MYC (8q24.1) rearrangement
Plasma Cell Leukemia
t(4;14) - FGFR3/IGH
t(6;14) - CCND3/IGH
t(11;14) - CCND1/IGH
t(14;16) - IGH/MAF
t(14;20) - IGH/MAFB
+1q or 1q22